Enveric Biosciences (ENVB)
(Real Time Quote from BATS)
$0.48 USD
0.00 (-0.62%)
Updated Aug 16, 2024 09:56 AM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ENVB 0.48 0.00(-0.62%)
Will ENVB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENVB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENVB
Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know
Enveric Biosciences, Inc. (ENVB) Stock Declines While Market Improves: Some Information for Investors
ENVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for April 17th
What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock
New Strong Buy Stocks for April 12th
Other News for ENVB
Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries? License for Treatment of Radiation Dermatitis and Other Conditions
Enveric Biosciences eligible for $61M in radiation dermatitis deal with Aries
Enveric Biosciences GAAP EPS of -$0.23
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results